---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-001569"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T19:56:10.385207+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NRx regains Nasdaq compliance; appoints Mike Taylor director amid $25M HOPE investment term sheet

## Summary
- Received Nasdaq notice on Jan 17 that it regained MVLS compliance; requirement met on Jan 16 after 10 consecutive trading days above $35M.
- Appointed Mike Taylor as Class I director, filling vacancy from Janet Rehnquist resignation, effective Jan 15.
- Taylor designated by JGS Holdings per term sheet for $25M in HOPE Series A Preferred convertible into 1/3 of HOPE equity and $2M for 730k NRXP shares.
- Nasdaq closed the matter, removing delisting risk from the Capital Market.

## SEC filing metadata
- accession: 0001437749-25-001569
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/nrxp20250122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-001569
- JSON: https://secwatch.observer/filing/0001437749-25-001569.json
- Plain text: https://secwatch.observer/filing/0001437749-25-001569.txt

## Key facts
- Executive change
  Mike Taylor was appointed as Director at NRX Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm
- Executive change
  Janet Rehnquist resigned as Director at NRX Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Director
  source text: Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774925001569/0001437749-25-001569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.